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Spread of Efflux Pump Overexpressing-Mediated 
Fluoroquinolone Resistance and Multidrug Resistance 
in Pseudomonas aeruginosa by using an Efflux Pump 
Inhibitor
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Background: Fluoroquinolone resistance in Pseudomonas aeruginosa may be due to efflux pump overexpression and/or target muta-
tions. We designed this study to investigate the efflux pump mediated fluoroquinolone resistance and check the increasing effective-
ness of fluoroquinolones in combination with an efflux pumps inhibitor among P. aeruginosa isolates from burn wounds infections.
Materials and Methods: A total of 154 consecutive strains of P. aeruginosa were recovered from separate patients hospitalized in a 
burn hospital, Tehran, Iran. The isolates first were studied by disk diffusion antibiogram for 11 antibiotics and then minimum inhibitory 
concentration (MIC) experiments were performed to detect synergy between ciprofloxacin and the efflux pump inhibitor, carbonyl cya-
nide-m-chlorophenyl hydrazone (CCCP).  Then to elucidate the inducing of multi drug resistance due to different efflux pumps activation 
in Fluoroquinolone resistant isolates, synergy experiments were also performed in random ciprofloxacin resistant isolates which have 
overexpressed efflux pumps phenotypically, using  CCCP and  selected antibiotics as markers for Beta-lactams and Aminoglycosides. 
The isolates were also tested by  polymerase chain reaction (PCR) for the presence of the MexA, MexC and MexE, which encode the 
efflux pumps MexAB-OprM, MexCD-OprJ and MexEF-OprN.
Results: Most of the isolates were resistant to 3 or more antibiotics tested. More than half of the ciprofloxacin resistant isolates 
exhibited synergy between ciprofloxacin and CCCP, indicating the efflux pump activity contributed to the ciprofloxacin resis-
tance. Also increased susceptibility of random ciprofloxacin resistant isolates of P. aeruginosa to other selected antibiotics, in 
presence of CCCP, implied multidrug extrusion by different active efflux pump in fluoroquinolones resistant strains. All of Cip-
rofloxacin resistant isolates were positive for MexA, MexC and MexE genes simultaneously.
Conclusion: In this burn hospital, where multidrug resistant P. aeruginosa isolates were prevalent, ciprofloxacin resistance and 
multidrug resistance due to the overexpression of fluoroquinolones mediated efflux pumps has also now emerged. Early recog-
nition of this resistance mechanism should allow the use of alternative antibiotics and use an efflux pumps inhibitor in combi-
nation with antibiotic therapy.
Key Words: Pseudomonas aeruginosa; Antibiotic therapy; Efflux pump; Ciprofloxacin, Carbonyl cyanide-m-chlorophenyl hydra-
zone; Burned patients
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Introduction
Pseudomonas aeruginosa is an opportunistic human 
pathogen and one of the leading causes of nosocomial infec-
tions worldwide [1] and causes a variety of infections especial-
ly in immunocompromised patients such as burned patients. 
Infections caused by P. aeruginosa are associated with signifi-
cant morbidity and mortality [2, 3]. The organism exhibits a 
high level of intrinsic resistance and only a limited number of 
antimicrobial agents are active against it [4]. In addition, P. 
aeruginosa has acquired multiple mechanisms of resistance 
against all available anti pseudomonal agents [4, 5]. Fluoro-
quinolones(FQ) are one of the major classes of antibiotics 
used in the treatment of infections caused by P. aeruginosa [1] 
and Large-scale surveillance studies have reported an increas-
ing rate of FQ resistance among clinical isolates of P. aerugi-
nosa [6]. Overexpression of efflux pumps (EPs) and Target 
based mutation in gyrase and/or topoisomerase contribute to 
FQ resistance [4]. Of note, in vitro data indicate that at FQ con-
centrations near the MIC, efflux mutants are preferentially se-
lected before target mutations [7]. Analysis of the genome se-
quence of P. aeruginosa revealed the existence of 12 potential 
resistance nodulation division (RND) efflux pump systems [1].
Of these, Six EPs have been well characterized thus far: Mex-
AB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM, Mex-
JK-OprM, and MexVW-OprM [8-10]. The first three have an 
important role in FQ resistances. All of the pumps can expel a 
variety of compounds ranging from detergents to structurally 
unrelated antimicrobial agents from the cytoplasm or peri-
plasmic space [10, 11]. While each pump has a preferential set 
of antimicrobial agent substrates, the FQs are universal sub-
strates for all known Mex pumps [12]. Phenotypic and genetic 
tests may be used in laboratories practice in order to identify 
the presence of acquired resistance due to efflux pump over-
expression among P. aeruginosa isolates. Increased expres-
sion of efflux pumps could increases the MICs of many anti-
microbials. A series of different compounds have been 
identified as efflux pump inhibitors (EPIs) with the ability to 
broadly inhibit several known multidrug EPs in P. aeruginosa. 
In this study the resistance due to overexpression of the efflux 
system was evaluated by phenotypic test using efflux pump 
inhibitor carbonyl cyanide 3-chlorophenylhydrazone (CCCP). 
CCCP is a known proton motive force and RND efflux pump 
inhibitor [13, 14], that can be added in Mueller-Hinton agar 
during its preparation. This phenotypic test is useful to detect 
efflux pump overexpression that contributes to or determines 
Fluoroquinolone and multi drug resistance in the study iso-
lates. The minimum inhibitory concentrations (MICs) of anti-
biotics for strains overexpressing an efflux pump are usually 2 
or more folds higher than those strains of that species which 
didn’t have overexpressing an efflux pump.In this study, we 
hypothesized that the FQ resistant among P. aeruginosa iso-
lated from burn wound infections (may be due to widespread 
use of FQ agents to treat burn wounds) could be in corporate 
with resistance to other existing antipseudomonal agents such 
as Beta-lactams and Aminoglycosides through FQ selected 
overexpression of multidrug efflux pumps. The specific aims 
of our study were to use CCCP as a screening agent to evalu-
ate (i) the prevalence of efflux pump-mediated resistance 
among clinical isolates of P. aeruginosa (ii) the contribution 
of efflux pumps overexpression as the supposed mechanism 
for the multi drug resistance (MDR) phenotype in P. aerugi-
nosa (iii) effectiveness increase of FQs in combined with an 
efflux pump inhibitor.
Table 1. Primers used in this study
Primer 5’-sequence-3’ Product length (bp) Reference
OprI-F ATGAACAACGTTCTGAAATTCTCTGCT
249 16
OprI-R CTTGCGGCTGGCTTTTTCCAG
OprL-F ATGGAAATGCTGAAATTCGGC
504 16
OprL-R CTTCTTCAGCTCGACGCGACG
mexA1 CGACCAGGCCGTGAGCAAGCAGC
316 24
mexA2 GGAGACCTTCGCCGCGTTGTCGC
mexC3 GTACCGGCGTCATGCAGGGTTC
164 24
mexC4 TTACTGTTGCGGCGCAGGTGACT
mexE4 CCAGGACCAGCACGAACTTCTTGC
114 24
mexE5 CGACAACGCCAAGGGCGAGTTCACC
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Materials and Methods
1. Bacterial isolates
The study included a total of 154 P. aeruginosa non repeti-
tive isolates recovered consecutively from clinical burn wound 
infections of separate patients at a burn hospital of Tehran, 
Iran. Bacterial isolates first were identified based on the stan-
dard biochemical tests [15]. Then phenotypic identification 
was confirmed at the species level by using PCR amplification 
of OprI and OprL gene [16] (Table 1). Bacterial genomic DNA 
was extracted from the all isolates, as well as from the refer-
ence strains of P.aeruginosa, by employment boiling method. 
For this purpose, all isolates were inoculated aerobically on 
nutrient agar for 18-24 hour at 37°C. Depending on colony 
size, three to six colonies were picked from plates and mixed 
in to 0.1 mL DNase/RNase-free water in sterile 1.5-mL tubes 
to obtain a turbid suspension of bacteria (~ 1–2 × 109 cells/ 
mL). The cell suspensions were held in a boiling water-bath 
for 10 min to lyse the cells and then centrifuged at 10,000 g at 
4°C for 10 minutes. Finally the supernatant transmitted in 
sterile conditions into another tube and used as DNA tem-
plate. Extracted DNA was stored at -20°C prior to PCR amplifi-
cation. Also all the confirmed P. aeruginosa isolates were 
stored at -70°C in Trypticase soy broth supplemented with 
10% glycerol until ready for testing. Control strains included 
PAO1 (wild type) [17] and P. aeruginosa ATCC 27853.
2. In vitro susceptibility testing 
First the antibacterial susceptibility testing of selected P. 
aeruginosa species was done by disk diffusion method on 
Mueller-Hinton Agar (Control S, Madrid, Spain). All isolates 
were tested for susceptibility to imipenem (10 μg), cefepime 
(30 μg), Ticarcillin (75 μg), Aztreonam(30 μg), Tobramycin (10 
μg), Gentamicin (10 μg), Colistin (25 μg), Amikacin (30 μg), 
Ciprofloxacin (5 μg), Piperacillin (100 μg), Piperacillin-tazo-
bactam (110 μg) (all from Mast, Merseyside. UK). Then, to in-
vestigate the prevalence of Efflux pump mediated FQ resis-
tance, synergy experiments were performed for all 154 strains 
of P. aeruginosa using ciprofloxacin, as a representative of FQ 
agents which are typically exported by all of 3 most important 
efflux pumps, and the efflux pump inhibitor. CCCP (Sigma-Al-
drich, ST. Louis, MO, USA) was incorporated in Mueller–Hin-
ton agar (Control S, Spain) at concentrations of 12.5 µm and 
ciprofloxacin susceptibility testing was performed by the two 
fold serial dilution method using a final inoculum of 106 cells/
mL in agar plates with and without CCCP [18]. Then to eluci-
date the inducing of multi drug resistance due to different ef-
flux pumps activation in Fluoroquinolone resistant isolates, 
synergy experiments were also performed in random cipro-
floxacin resistant isolates which have overexpressed efflux 
pumps phenotypically, using CCCP and antibiotics selected 
as markers for beta-lactams [imipenem (IMI) & cefepime 
(CEF)] and Aminoglycosides [gentamicin (GEN)]. P. aerugi-
Figure 1. The susceptibility status of the isolates against 11 studied antibiotics according to disk diffusion. IMI, imipenem; CEF, cefepime; TC, ticarcil-
lin; AT, aztreonam; TOB, tobramycin; GN, gentamicin; CO, colistin; CIP, ciprofloxacin; AK, amikacin; PTZ, piperacillin-tazobactam; PIP, piperacillin.
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nosa ATCC 27853 and PAO1 was used as reference strain [19]. 
Both of these methods were carried out according to the 
guidelines established by the clinical and laboratory stan-
dards institute (CLSI) [20]. The latter synergy tests were per-
formed in order to check the contribution of efflux pumps to 
the resistance to FQs, Beta-lactams and Aminoglycosides that 
are selectively extracted by FQ mediated efflux pumps com-
monly found in pseudomonads [ 21].
3. PCR for Mex-Opr efflux systems
To investigate the ratio between existing the different EPs 
genes and overexpressed efflux pumps ranges, all  the isolates 
were tested by PCR for the presence of MexA, MexC and 
MexE genes, which are representative of MexAB-OprM, Mex-
CD-OprJ and MexEF-OprN efflux systems respectively, using 
previously described primers [18, 22]. Primer designation and 
their sequences are shown in Table 1.  
Results
154 strains of P. aeruginosa were isolated from hospitalized 
burned patients and confirmed using biochemical tests and 
confirmatory PCR assays. The antibiogram results represent-
ing 143 (92.8%) of the P. aeruginosa isolates exhibiting resis-
tance to two or more antibiotics. According to our anti-
biogram results, all of the isolates only were susceptible to 
colistin. The most resistance was seen against tobramycin 
(87.7%) and the least resistance was seen against aztreonam 
(71.4%).The preliminary results of ciprofloxacin susceptibility 
test using the disk agar diffusion method showed that 85.1% of 
the P.aeruginosa strains were resistant to this antibiotic. Fig-
ure 1 summarizes the susceptibility status of the isolates 
against 11 studied antibiotics according to disk diffusion 
method. MIC for ciprofloxacin ranged from 0.5 to 128 mg/L, 
According to the established breakpoint values recommended 
by CLSI [20]. The P.aeruginosa isolates with MIC ≥ 4 mg/L are 
considered as ciprofloxacin resistant. The preliminary results 
of ciprofloxacin susceptibility test using the MIC method 
showed that 127 (82.5%) of the P. aeruginosa strains were re-
sistant to this antibiotic. Results of Synergy tests indicated that 
by using CCCP as EPI, the MICs of ciprofloxacin for 51 (61%) 
of the ciprofloxacin resistant isolates decreased (2 to 256 
folds) on the CCCP-supplemented plate. Table 2 shows the Ef-
fects of CCCP on the Ciprofloxacin MIC reduction in cipro-
floxacin resistant isolates of P. aeruginosa. Also in other syn-
ergy tests by using CCCP and other antibiotics, we observed 
increased susceptibility of random selected ciprofloxacin re-
sistant isolates to selected antibiotics as markers for beta-lact-
ams [imipenem (IMI) & cefepime (CEF)] and Aminoglyco-
sides [gentamicin (GEN)]. Table 3 shows the MIC values for 
ciprofloxacin measured in the absence and in the presence of 
12.5 µm CCCP as efflux pump inhibitor in clinical strains of P. 
aeruginosa. The MexA, MexC and MexE genes were ampli-
fied by PCR in 147 (95.4%) isolates simultaneously, and 5 
(3.2%) isolates revealed the presence of MexA and MexE si-
multaneously. 1 (0.6%) isolate had only the MexE gen and 1 
(0.6%) had none of the Mex genes. All of the ciprofloxacin re-
sistant isolate had MexA, MexC and MexE genes simultane-
ously. 
Discussion
The findings of the present study clearly show the high inci-
dence of resistant P. aeruginosa strains in burned patients for 
most of the antibiotics tested. It seems that resistance of P. 
aeruginosa to most therapeutically antibiotics is common in 
burned patients of Iran. Almost of the isolates were resistant 
to two or more antibiotics tested, except colistin showing the 
highest (100%) antibacterial activity. Only 8 (5.2%)  P. aerugi-
nosa isolates were fully susceptible. In case of ciprofloxacin as 
an important therapeutically choice for P. aeruginosa we ob-
served resistance among 85% of isolates and all of ciprofloxa-
cin-resistant P. aeruginosa were resistant to one or more oth-
er tested antibiotics except colistin with no detected resistance. 
It could be a reason to approve our hypothesis that the FQ re-
sistant among P. aeruginosa isolated from burn wound infec-
tions could be in coordinate with resistance to other existing 
Table 2. Effects of CCCP on the Ciprofloxacin MIC in resistant isolates of 
P. aeruginosa
Ciprofloxacin Resistant  
isolates, No. (%)
Fold reduction 
in MIC + CCCP
  49 (39%)     0
  42 (33%)     2
10 (8%)     4
  4 (3%)     8
  5 (4%)   16
  8 (6%)   32
  1 (1%)   64
  0 (0%) 128
  8 (6%) 256
CCCP, carbonyl cyanide-m-chlorophenylhydrazone; MIC, minimal inhibitory con-
centration.
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antipseudomonal agents through overexpression of FQ medi-
ated multidrug efflux pumps, because these efflux pumps 
have broad substrate specificity, and extrude many antibiotic 
classes including B-lactams, quinolones and aminoglyco-
sides[18]. Widespread use of FQ agents could be one of the 
main reasons to inducing FQ resistance among P. aeruginosa 
isolated from burn wound infections, so it has an adverse col-
lateral effect on the susceptibility of P. aeruginosa to other ex-
isting antipseudomonal agents through FQ selected overex-
pression of multidrug efflux pumps. To more examination of 
this assumption, we employed the EPI compound, CCCP, to 
phenotypic investigation of efflux pump-overexpressed in 
clinical isolates of P. aeruginosa. Its why that the susceptibility 
of P. aeruginosa strains to antimicrobial agents can be signifi-
cantly enhanced by pump inactivation [21]. According to our 
observations, many of clinical isolates of P. aeruginosa with a 
wide range of resistance phenotypes showed increased sus-
ceptibilities to ciprofloxacin in the presence CCCP and the 
MIC of more than half of ciprofloxacin resistant strains de-
creased two or more fold and the ratio of sensitive strains in-
creased from 25% to 51%. The result of synergy tests observed 
between CCCP and ciprofloxacin approved its selective extru-
sion by the above efflux systems contribute to the ciprofloxa-
cin resistance. The genetically investigation of existence of 
MexA, MexC and MexE genes, which are representative of 
MexAB-OprM, MexCD-OprJ and MexEF-OprN efflux systems 
respectively, showed that all of ciprofloxacin resistant strains 
have these 3 Mex genes simultaneously, but according to phe-
notypic investigation of efflux pump, half of them showed 
overexpression of multidrug efflux pumps, so fortunately 
some of Eps are yet inactive.  Also Increased susceptibility of 
ciprofloxacin resistant P. aeruginosa isolates to selected anti-
biotics as markers for Beta-lactams [imipenem (IMI) & 
cefepime (CEF)] and Aminoglycosides [gentamicin (GEN)], in 
the presence of CCCP implied multidrug extrusion by differ-
ent active FQ mediated efflux pump in FQ resistant strains. 
After the addition of CCCP, the accumulation of antibiotics 
could have increased, and thus led to lower MICs for P. aeru-
ginosa isolates. Inhibition of efflux by CCCP in some isolates 
brought MICs down even to a level similar to those sensitive 
strains of P. aeruginosa. So efflux pumps have an important 
role in FQ resistant isolates of P. aeruginosa as an important 
Table 3. Ciprofloxacin resistant strains of P. aeruginosa used in this study and MICs of the four antibiotics selected as markers for Beta-lactams [Imi-
penem (IMI) & Cefepime (CEF)], Fluoroquinolones [Ciprofloxacin (CIP)] and Aminoglycosides [Gentamicin (GEN)] tested in the absence or in the presence 
of the efflux inhibitor CCCP
 Strains
MIC (mg/L)
IMI   CEF   CIP   GEN
-CCCP +CCCP -CCCP +CCCP -CCCP +CCCP -CCCP +CCCP
208 256 4 1,024 0.5 128 0.5   4 2
209 128 4 1,024 0.5 128 0.5 1,024 1
211 256 4 1,024 0.5 128 0.5 1,024 1
212 256 2 1,024 0.5 128 0.5 1,024 1
215 256 8 1,024 8 128 0.5 1,024 1
322 128 128 1,024 0 128 0.5 32 1
477 256 4 512 512 8 0.5 256 128
481 32 8 64 32 16 2 1,024 512
483 32 8 64 64 16 1 1,024 512
488 128 8 64 32 16 0.5 128 64
517 256 128 1,024 512 8 0.5 256 256
520 256 128 1,024 1,024 16 0.5 256 256
529 128 64 512 256 16 0.5 128 16
538 256 256 1,024 512 16 0.5 256 128
539 64 4 512 256 16 0.5 128 128
599 128 64 1,024 64 16 0.5   128 64
PAO1 2 2 0.5 0.5 1 1 2 2
-CCCP, in the absence of carbonyl cyanide-m-chlorophenylhydrazone; +CCCP, in the presence of carbonyl cyanide-m-chlorophenylhydrazone.
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and clinically refractory organism. A major beneficial conse-
quence of inhibition of multiple efflux pumps demonstrated 
in this study is a notable decrease in the frequency of emer-
gence of P. aeruginosa strains with clinically relevant levels of 
resistance to fluoroquinolones, also the efflux pump inhibitors 
appears to be an attractive approach to improvement of the 
clinical efficacies of other antibiotics that are substrates of 
such pumps [23]. Because the FQs are universal substrates for 
all known Mex pumps [10, 12]. Thus, FQ exposure as one of 
the main reasons to inducing FQ resistance among P. aerugi-
nosa isolated from burn wound infections, could has the pos-
sibility to select for mutants with the multidrug resistant phe-
notype via efflux pump overexpression. By inhibiting Efflux 
pumps in combination with antibiotic therapy we could over-
come some resistance among P. aeruginosa isolates. However 
we should consider the prevalence of efflux mediated resis-
tance, besides other mechanisms that contribute to resistance 
to a particular antibiotic and interactions between different 
mechanisms of resistance. From our experience with clinical 
isolates of P. aeruginosa recovered from burned patients, it is 
evident that the utility of Efflux pump inhibitors should be in 
combination with antibacterial agents for antibacterial thera-
py; these compounds may prove to be very useful for study of 
the contribution and prevalence of efflux in acquired and in-
trinsic resistance to multiple antibiotics in other gram-nega-
tive bacteria.
Most of resistance to FQs among pseudomonades contrib-
ute to constitutively expressed efflux pumps. Therefore, efflux 
pump inhibitors are expected to enhance the activities of FQs. 
FQ mediated efflux pumps from other gram negative bacteria 
also belong to the same family of transporters. This increases 
the possibility that a single inhibitor might be active against 
multiple efflux pumps [23]. While initial reports have demon-
strated the multifactorial benefits of the Efflux pump inhibitor 
approach in combating drug resistance; substantial efforts are 
needed before inhibitors can be used clinically. Our efforts are 
focused on the evaluation of the activities of the CCCP agent. 
Should our preliminary observations be confirmed in larger 
studies, it could be of importance to the ongoing efforts to elu-
cidate the mechanisms of Efflux pumps mediated resistance 
development and identify clinically applicable inhibitors.
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